Capricor Therapeutics (NASDAQ:CAPR) Receives Buy Rating from HC Wainwright

Key Points

• HC Wainwright has restated a "buy" rating for Capricor Therapeutics (NASDAQ:CAPR) with a target price of $24.00, indicating a potential upside of 280.35% from the current trading price.
• Despite the positive outlook from HC Wainwright, other analysts have varied opinions, with Roth Capital reducing their price target from $31.00 to $12.00 while maintaining a "buy" rating.
• Capricor Therapeutics recently reported a loss per share of ($0.57) for the quarter, missing analysts' estimates and highlighting ongoing financial challenges for the company.

HC Wainwright reiterated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR - Free Report) in a report published on Thursday morning,Benzinga reports. They currently have a $24.00 target price on the biotechnology company's stock.

A number of other research analysts also recently commented on the stock. Piper Sandler reissued an "overweight" rating and issued a $20.00 price objective on shares of Capricor Therapeutics in a research report on Friday, July 11th. Oppenheimer decreased their price objective on shares of Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating for the company in a research report on Monday, June 23rd. Cantor Fitzgerald reissued an "overweight" rating and issued a $30.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. Jones Trading decreased their price objective on shares of Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating for the company in a research report on Wednesday, June 25th. Finally, Wall Street Zen downgraded shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $22.56.

Capricor Therapeutics Price Performance

CAPR stock traded up $0.16 during midday trading on Thursday, hitting $6.20. The company's stock had a trading volume of 485,463 shares, compared to its average volume of 1,926,592. Capricor Therapeutics has a twelve month low of $4.59 and a twelve month high of $23.40. The company's fifty day moving average price is $7.31 and its 200 day moving average price is $9.71. The stock has a market capitalization of $283.46 million, a P/E ratio of -3.78 and a beta of 0.73.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.71%. Equities analysts expect that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Nuveen Asset Management LLC raised its position in shares of Capricor Therapeutics by 392.7% in the 4th quarter. Nuveen Asset Management LLC now owns 169,111 shares of the biotechnology company's stock valued at $2,334,000 after buying an additional 134,791 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Capricor Therapeutics by 22.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company's stock valued at $178,000 after buying an additional 2,361 shares in the last quarter. Two Sigma Investments LP raised its position in shares of Capricor Therapeutics by 223.6% in the 4th quarter. Two Sigma Investments LP now owns 119,047 shares of the biotechnology company's stock valued at $1,643,000 after buying an additional 82,254 shares in the last quarter. Voya Investment Management LLC acquired a new position in shares of Capricor Therapeutics in the 4th quarter valued at approximately $150,000. Finally, Bank of America Corp DE raised its position in shares of Capricor Therapeutics by 938.9% in the 4th quarter. Bank of America Corp DE now owns 170,543 shares of the biotechnology company's stock valued at $2,353,000 after buying an additional 154,127 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.